The Conversation (0)
Miraculins Inc. (TSXV:MOM) has provided pre-submission documentation to the U.S. Food and Drug Administration on the de novo classification of its Scout® diabetes device. This is the next step towards securing market clearance in the US.
As quoted in the press release:
Based on interactions with the FDA in 2014, including a meeting between a Miraculins delegation and FDA representatives in Washington, D.C., the Company is of the view that there is no predicate device for the Scout®, and that the de novo process could provide the appropriate regulatory pathway for market clearance in the U.S.
Click here to read the Miraculins Inc. (TSXV:MOM) press release
Click here to see the Miraculins Inc. (TSXV:MOM) profile.